228 related articles for article (PubMed ID: 24956294)
21. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic and biological parameters predicting the prognosis in endometrial cancer.
Kim JW; Kim SH; Kim YT; Kim DK
Yonsei Med J; 2002 Dec; 43(6):769-78. PubMed ID: 12497661
[TBL] [Abstract][Full Text] [Related]
23. Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy.
Aoki Y; Kase H; Watanabe M; Sato T; Kurata H; Tanaka K
Gynecol Oncol; 2001 Oct; 83(1):1-5. PubMed ID: 11585406
[TBL] [Abstract][Full Text] [Related]
24. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy for high-risk early-stage endometrial cancer.
Kodama J; Seki N; Hiramatsu Y
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):42-7. PubMed ID: 17218851
[TBL] [Abstract][Full Text] [Related]
26. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions.
Sehouli J; Koensgen D; Oskay-Ozcelik G; Mustea A
Crit Rev Oncol Hematol; 2008 Sep; 67(3):204-12. PubMed ID: 18407513
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience.
Lan C; Huang X; Cao X; Huang H; Feng Y; Huang Y; Liu J
Expert Opin Pharmacother; 2013 Apr; 14(5):535-42. PubMed ID: 23480059
[TBL] [Abstract][Full Text] [Related]
29. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
30. Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer.
Scholz HS; Petru E; Gücer F; Haas J; Tamussino K; Winter R
Anticancer Res; 2000; 20(5C):3983-5. PubMed ID: 11268488
[TBL] [Abstract][Full Text] [Related]
31. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
Moore KN; Tian C; McMeekin DS; Thigpen JT; Randall ME; Gallion HH
Cancer; 2010 Dec; 116(23):5407-14. PubMed ID: 20737572
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for advanced endometrial cancer with carboplatin and epirubicin.
Tirmazy SH; Barthakur U; El-Modir A; Anwar S; Fernando I
Anticancer Res; 2014 Jul; 34(7):3793-8. PubMed ID: 24982404
[TBL] [Abstract][Full Text] [Related]
33. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
34. Postoperative adjuvant chemotherapy in surgically staged grade 3 endometrial cancer.
Takeshima N; Ota T; Omatsu K; Hasumi K; Takizawa K
Anticancer Res; 2008; 28(3B):1785-8. PubMed ID: 18630460
[TBL] [Abstract][Full Text] [Related]
35. [Adjuvant chemotherapy for high-risk endometrial carcinoma].
Komatsu M; Takehara K; Fujii T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():356-9. PubMed ID: 15535267
[No Abstract] [Full Text] [Related]
36. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
Yahata H; Hirakawa T; Fujita T; Ariyoshi K; Sonoda K; Amada S; Kobayashi H; Nakano H
Int J Clin Oncol; 2004 Aug; 9(4):317-21. PubMed ID: 15375709
[TBL] [Abstract][Full Text] [Related]
37. [Hormonal therapy and chemotherapy of endometrial cancer].
Krauss T; Huschmand H; Hinney B; Viereck V; Emons G
Zentralbl Gynakol; 2002 Jan; 124(1):45-50. PubMed ID: 11873314
[TBL] [Abstract][Full Text] [Related]
38. Endometrial carcinoma: clinical characteristic and survival rates by the new compared to the prior FIGO staging systems.
Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Khunnarong J; Pataradool K; Thavaramara T
J Med Assoc Thai; 2013 May; 96(5):505-12. PubMed ID: 23745302
[TBL] [Abstract][Full Text] [Related]
39. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
40. Disease-free interval after primary treatment predicts prognosis of recurrent endometrial carcinoma.
Ueda Y; Matsumura Y; Egawa-Takata T; Miyake T; Miyatake T; Yoshino K; Fujita M; Matsuzaki S; Yokoyama T; Miyoshi Y; Yamasaki M; Enomoto T; Kimura T
Anticancer Res; 2010 Oct; 30(10):4347-52. PubMed ID: 21036762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
